Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic.
The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance.
This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites.
1. Cover image - p. iv 2. Title page - p. iv 3. Table of Contents - p. iv 4. Copyright - p. iv 5. Aims and Scope for Series "Cancer Sensitizing Agents for Chemotherapy" - p. v 6. About the Series Editor - p. vii 7. About the Editor - p. ix 8. Aims and Scope for "Improving the Therapeutic Ratio in Head and Neck Cancer" - p. xi 9. Preface - p. xiii 10. Contributors - p. xxi 11. Chapter 1: Overview of head and neck cancer management - p. xxiii 12. Chapter 2: The role of molecularly targeted therapies and immunotherapy in head and neck cancer - p. 32 13. Chapter 3: Combining radiation and chemotherapy to improve the therapeutic ratio - p. 47 14. Chapter 4: Targeting TP53 to augment therapeutic response in head and neck cancer - p. 63 15. Chapter 5: Modulation of the PI3K/mTOR pathways - p. 88 16. Chapter 6: Improving responses to immunotherapy in head and neck squamous cell carcinoma - p. 105 17. Chapter 7: Overcoming head and neck cancer stem cells - p. 133 18. Chapter 8: TAM family proteins and therapy resistance - p. 157 19. Chapter 9: Eph/ephrin family proteins and therapeutic resistance - p. 192 20. Chapter 10: Manipulating redox active metal metabolism to enhance cancer therapy - p. 220 21. Chapter 11: Fibroblast growth factor receptors as therapeutic targets in head and neck squamous cell carcinomas - p. 234 22. Chapter 12: The MET receptor as a therapeutic target in head and neck squamous cell carcinomas - p. 261 23. Chapter 13: Autophagy in head and neck cancer therapy - p. 280 24. Chapter 14: Combining Chk1/2 inhibition with radiation in head and neck cancer - p. 300 25. Chapter 15: GPCRs in head and neck squamous cell carcinoma - p. 316 26. Chapter 16: Clinical trial design in head and neck cancer-challenges and opportunities - p. 334 27. Index - p. 347
Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic.
The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance.
This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites.
1. Cover image - p. iv 2. Title page - p. iv 3. Table of Contents - p. iv 4. Copyright - p. iv 5. Aims and Scope for Series "Cancer Sensitizing Agents for Chemotherapy" - p. v 6. About the Series Editor - p. vii 7. About the Editor - p. ix 8. Aims and Scope for "Improving the Therapeutic Ratio in Head and Neck Cancer" - p. xi 9. Preface - p. xiii 10. Contributors - p. xxi 11. Chapter 1: Overview of head and neck cancer management - p. xxiii 12. Chapter 2: The role of molecularly targeted therapies and immunotherapy in head and neck cancer - p. 32 13. Chapter 3: Combining radiation and chemotherapy to improve the therapeutic ratio - p. 47 14. Chapter 4: Targeting TP53 to augment therapeutic response in head and neck cancer - p. 63 15. Chapter 5: Modulation of the PI3K/mTOR pathways - p. 88 16. Chapter 6: Improving responses to immunotherapy in head and neck squamous cell carcinoma - p. 105 17. Chapter 7: Overcoming head and neck cancer stem cells - p. 133 18. Chapter 8: TAM family proteins and therapy resistance - p. 157 19. Chapter 9: Eph/ephrin family proteins and therapeutic resistance - p. 192 20. Chapter 10: Manipulating redox active metal metabolism to enhance cancer therapy - p. 220 21. Chapter 11: Fibroblast growth factor receptors as therapeutic targets in head and neck squamous cell carcinomas - p. 234 22. Chapter 12: The MET receptor as a therapeutic target in head and neck squamous cell carcinomas - p. 261 23. Chapter 13: Autophagy in head and neck cancer therapy - p. 280 24. Chapter 14: Combining Chk1/2 inhibition with radiation in head and neck cancer - p. 300 25. Chapter 15: GPCRs in head and neck squamous cell carcinoma - p. 316 26. Chapter 16: Clinical trial design in head and neck cancer-challenges and opportunities - p. 334 27. Index - p. 347
